Skip to main content

Table 2 Multivariable Analysis for PFS and OS including NER

From: Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

 

PFS

OS

 

AHR (95% CI)

P-value

AHR (95% CI)

P-value

NER

 <Median

0.62 (0.39–0.98)

0.04

0.32 (0.14–0.72)

0.006

 >Median

Ref

 

Ref

 

Age

 Age > 60

0.82 (0.51–1.31)

0.41

1.06 (0.51–2.19)

0.88

 Age < 60

Ref

 

Ref

 

Race

 Non-White

0.65 (0.30–1.41)

0.28

0.42 (0.10–1.83)

0.25

 White

Ref

 

Ref

 

Sex

 Male

1.02 (0.61–1.69)

0.95

1.32 (0.57–3.06)

0.52

 Female

Ref

 

Ref

 

IMDC

 Poor

2.36 (1.08–5.14)

0.03

3.81 (0.95–15.33)

0.06

 Intermediate

1.31 (0.69–2.46)

0.41

1.95 (0.57–6.71)

0.29

 Favorable

Ref

 

Ref

 

Prior systemic therapy

 Yes

1.78 (1.09–2.90)

0.02

0.69 (0.29–1.62)

0.39

 No

Ref

 

Ref

Â